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Abstract
Background—Mutations in the gene coding for the transmembrane activator and calcium-
modulating cyclophilin ligand interactor (TACI) are found in 8% to 10% of subjects with common
variable immunodeficiency (CVID). Although heterozygous mutations may coincide with
immunodeficiency in a few families, most mutation-bearing relatives are not
hypogammaglobulinemic. Thus, the role of TACI mutations in producing the immune defect
remains unclear.
Objective—This study examined the expression and function of TACI mutations in healthy
heterozygous relatives.
Methods—We examined the surface and intracellular expression of TACI protein in EBV-
transformed B cells of patients and relatives with mutations in 7 families, binding of a
proliferation-inducing ligand, and secretion of IgG and IgA by ligand-activated B cells. We tested
whether Toll-like receptor 9 agonists increased TACI expression and whether an agonistic anti-
TACI antibody could induce activation-induced cytidine deaminase mRNA in those with
mutations.
Results—Intracellular and extracellular TACI expression was defective for B cells of all subjects
with mutations, including subjects with CVID and relatives. Although Toll-like receptor 9
triggering normally up-regulates B-cell TACI expression, this was defective for all subjects with
mutations. Triggering TACI by an agonistic antibody showed loss of activation-induced cytidine
deaminase mRNA induction in all mutation-bearing B cells. However, ligand-induced IgG and
IgA production was normal for healthy relatives but not for subjects with CVID.
Conclusion—Thus, B cells of relatives of subjects with CVID who have mutations in TACI but
normal immune globulin levels still have detectable in vitro B-cell defects.
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Common variable immunodeficiency (CVID) is a heterogeneous primary immunodeficiency
disease complex characterized by low levels of serum IgG and IgA and/or IgM coupled with
antibody deficiency.1 The syndrome includes impaired B-cell maturation, impaired somatic
hypermutation, reduced numbers of circulating memory and isotype-switched memory B
cells, and diminished maturation of plasma cells.2–4 That the CVID syndrome is caused by
mutations in a number of genes potentially contributing to the diverse phenotypes5–7 is
supported by the identification of autosomal recessive mutations in the inducible
costimulator, CD19, CD81, CD20, CD21, and B cell-activating factor (BAFF) in a few
cases.8–12 However, more complex from the viewpoint of pathogenesis are mutations in the
transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI,
TNFRSF13B), identified in about 8% to 10% of patients but sometimes found in healthy
subjects who are not hypogammaglobulinemic.13–17
TACI is a cell membrane receptor for 2 ligands, a proliferation-inducing ligand or APRIL
(TNFSF13) and BAFF (TNFSF13B). BAFF also binds with high affinity to the BAFF
receptor but poorly to a third B-cell receptor, B-cell maturation antigen (BCMA). By
contrast, APRIL binds only to TACI but much less well to BCMA.18–20 TACI protein is
expressed on the surface of B cells, in particular marginal zone and CD27+ memory B cells
and is upregulated on activation by Toll-like receptor 9 (TLR9).21 Appropriate activation of
TACI leads to B-cell differentiation, up-regulation of activation-induced cytidine deaminase
(AID) mRNA, isotype switch, and maturation to immunoglobulin production, leading
especially to T cell-independent antibody production.18,20,22–25 As for other TNF family
members, TACI functions as a trimer; the first cysteine-rich domain (CDR1) has been
suggested as important for the preassembly of TACI into trimers or larger multimers,
independently of ligand interactions.23 The second CRD is essential for the binding of both
BAFF or APRIL to TACI.19 Downstream, TACI signaling proteins include TNF-R–
associated factors and calcium-modulator and cyclophilin ligand, subsequently activating
nuclear factor-κB via the canonical pathway and ultimately intersecting with myeloid
differentiation antigen (MYD88), which is also required for signaling.21
Subjects with CVID have both homozygous and heterozygous mutations in the extracellular,
transmembrane, and intracellular regions of TACI.13–17 The extracellular mutation (C104R)
leads to a disruption of the second CRD, impairing BAFF and APRIL binding.19 The C104R
and A181E mutations lead to signaling impairments and defective antibody production in
vivo in homologous murine models.24,25 These and other TACI transmembrane or
intracytoplasmic mutations in CVID are presumed to lead to impaired BAFF and APRIL
signaling, loss of class switch, and ultimately hypogammaglobulinemia. Although TACI
mutations are significantly associated with CVID17 and occasionally with immune
deficiency in first-degree relatives of patients with CVID,13–16 family members with
heterozygous mutations are much more commonly healthy and not
hypogammaglobulinemic, leading to questions about the function of this receptor. However,
the loss of 1 functional allele might lead to degree of haploinsufficiency,26 potentially
relevant for a trimeric receptor that has stringent binding requirements for a multimerized
ligand.27 This hypothesis does not however explain why relatives are more commonly not
immune deficient and suggests the presence of additional defects in patients. We have
shown that subjects with Smith-Magenis syndrome, who commonly have only 1 copy of
TACI because of deletions on chromosome 17, have impaired TACI expression, loss of
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ligand binding, and poorer anticarbohydrate anybody production.28 In the present study we
show that family members with the same mutations in heterozygous or homozygous form,
although not hypogammaglobulinemic, still have impaired B-cell TACI expression, reduced
ligand binding, and markedly defective upregulation of AID mRNA, showing a dominantly
inherited, selective in vitro activation defect.
METHODS
Patients, families, B-cell lines
Peripheral blood B cells of patients with CVID with heterozygous, compound heterozygous,
or homozygous mutations in TACI in 7 families and their first-degree relatives were studied.
Clinical histories and serum immune globulins for all subjects with antibody evaluations for
patients were obtained (Tables I and II). Genomic DNAwas examined for TACI mutations
as described.16 Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized
peripheral blood by Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient
centrifugation. EBV-transformed B cell lines were produced from peripheral blood B cells
of these subjects and healthy controls and cultured at 37°C in RPMI 1640 medium (Gibco,
Carlsbad, Calif) with L-glutamine and 10% heat-inactivated fetal calf serum (FCS). Family
F, containing both parents with C104R heterozygous mutations and 3 children with
homozygous C104R defects, only 2 of whom have hypogammaglobulinemia, has previously
been described (Table I).29
Extracellular and intracellular TACI expression; APRIL binding
Surface expression of TACI on B cells of EBV-transformed B-cell lines from subjects with
CVID, family members, and healthy controls was determined by flow cytometry with the
use of biotinylated polyclonal goat anti-TACI antibody or a control biotinylated goat-IgG
(R&D Systems, Minneapolis, Minn) and secondary staining with streptavidin-phycoerythrin
(BD Pharmingen, San Diego, Calif). Intracellular TACI expression was determined with
goat anti-TACI antibody, after treatment with 1% saponin in complete medium with FCS for
permeabilization, followed by streptavidin-phycoerythrin staining. To assess TACI binding
of the ligand APRIL, EBV B cells were incubated with 250 ng/mL FLAG-tagged
MegaAPRIL (Axxora, San Diego, Calif) on ice in the presence of heparin (1000 U/mL); 1
μg/mL biotin-anti-FLAG monoclonal M2 antibody (Sigma, St Louis, Mo) was then added.
The cells were washed and examined with streptavidin- phycoerythrin. Flow cytometry
(fluorescence-activated cell sorting or FACS) was performed with a FACSCalibur (Becton
Dickinson, Mountain View, Calif.)
TLR9 activation and TACI expression
Stimulation of B cells by TRL-9 ligation normally enhances the expression of TACI on
normal B cells.21 To determine whether upregulation of TACI occurs for B cells of subjects
with CVID with mutations, we incubated EBV cells or peripheral blood B cells with the
cytosine phosphate guanine (CpG)–DNA TLR9 activator, ODN2006 (Invivogen, San Diego,
Calif) at 0, 0.6, 1.5, and 3.0 μg/mL for 48 hours and examined the surface expression of
TACI on B cells by FACS as described in the Extracellular and intracellular TACI
expression; APRIL binding section.
TACI-induced AID mRNA
Triggering TACI initiates the upregulation of AID mRNA in both normal B cells and EBV-
transformed B-cell lines.23 To examine the effects of TACI mutations, we tested EBV B
cells of subjects with CVID with compound heterozygous mutations from families C, E, and
F, as well as B cells from relatives with the same mutations in heterozygous form, compared
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with EBV cells of healthy controls. For this, 5 × 104 B cells were cultured in 48-well plates
with a 1 μg/mL of an agonistic biotin-conjugated TACI mAb (11H3; eBioscience, San
Diego, Calif) or isotype control, with or without 100 ng/mL IL-4 or IL-10 (R&D Systems)
for 48 hours. To further crosslink TACI receptors, 5 mL of antibiotin microbeads IgG
microbeads (Miltenyi Biotec, Cambridge, Mass) was added. AID mRNA was isolated
(RNeasy Mini Kit; Qiagen, Valencia, Calif) and reverse transcribed (SuperScript III First-
Strand cDNA synthesis kit; Invitrogen, Carlsbad, Calif). Quantitative real-time PCR was
performed with LightCycler Real-Time PCR system and FastStart DNA Master SYBR
Green I kit (Roche Diagnostics, Indianapolis, Ind), using β-actin mRNA as control for copy
number. The following primers were used for AID mRNA: (5′-
TGCTCTTCCTCGGCTACATCTC-3′; 5′-AACCTCATACAGGGGCAAAAGG-3′) and
β-actin (5′-CTGAACCC CAAGGCCAACAG-3′; 5′-
CCAGAGAAGAGGAGGATGCG-3′).16
IgG and IgA production
Peripheral mononuclear cells of patients and family members or healthy controls were
incubated with MegaAPRIL (200 ng/mL; Axxora), with or without IL-10 (10 ng/mL; R&D
Systems) or CD40-ligand (300 ng/mL; Axxora) plus IL-10 for 12 days in complete medium
containing 10% FCS. The cell supernatant fluids of these cultures were then tested for IgG
and IgA content with the use of sandwich ELISA reagents (Bethyl Laboratories,
Montgomery, Tex).
Statistical analyses
The Spearman correlation test was used to compare intracellular and extracellular
expressions of TACI in lymphoblastoid cell lines, using 95% confidence intervals. To
compare TACI expression for B cells of groups of subjects or to compare the ability of
lymphoblastoid B cells of patients, relatives, and controls to bind the ligand APRIL, the
nonparametric 2-tailed Mann-Whitney test was used. This test was also used in comparisons
of mRNA induction in B cells of subjects with mutations and controls and to examine
differences for IgG and IgA production for subjects with CVID, relatives, and controls. To
consider the effects of multiple comparisons, some data sets were also examined with one-
way ANOVA. All data were analyzed with GraphPad Prism software, considering P ≤.05 to
be significant.
RESULTS
Patients and mutational analyses
The baseline serum immunoglobulins and clinical histories of patients with CVID with
heterozygous, compound heterozygous, or homozygous TACI mutations and their first-
degree relatives in 7 families are shown on Table I. Table II provides further data, when
available, on antibody production for the subjects with CVID before immunoglobulin
replacement. As previously reported, the predominant mutations were C104R and A181E,
but other mutations were also found. Subjects with CVID in each family are identified by
the low serum levels of IgG, IgA, and IgM. Family members also with TACI mutations had
normal serum immune globulins, with the exceptions of both brothers E.III and E.IV (each
with S194X stop codons) who had reduced serum IgG and especially low serum levels of
IgM. Neither had any significant clinical history of infections or other illnesses. Although
autoimmunity was common in the patients,16 most family members were healthy; however,
the sister of patient A.I had ulcerative colitis and was known to have anticardiolipin
syndrome that led to fetal loss, and the sister of E.I. (E.IV) died of an overwhelming
pseudomonas infection of unknown origin.
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Mutations lead to impaired expression of intracellular and extracellular TACI
B cells from EBV cell lines from patients and their family members were examined to
compare the surface and intracellular protein expression of TACI with control EBV B cells
from healthy donors. Fig 1 shows that cells of all patients (open circles) identified in their
respective families had significantly less TACI expression (surface or intracellular) than
cells of their family members with the same mutations (shaded open circles) compared with
the healthy controls (Mann-Whitney test: patients to controls, P = .01; relatives to controls,
P = .04). In addition, for all cells examined, extracellular and intracellular expressions of
TACI were highly significantly related (P < .0001, Spearman r = 0.86.) However, B cells of
both family members and patients had less intracellular and extracellular expressions of
TACI than B cells of the healthy controls (filled circles) (P =.01 and .008).
Heterozygous and homozygous mutations impair APRIL binding
The capacity of mutated TACI receptors on lymphoblastoid B cells of both patients and
family members to bind the ligand APRIL was then compared with that of B cells of healthy
controls (Fig 2). Although the heterozygous C104R mutation would be likely to impair
ligand binding, B cells of both patients and relatives with all the other heterozygous
mutations were also impaired, suggesting that, as for TACI expression, reduced ligand
binding is another general feature of the heterozygous state. The ability of normal EBV cells
to bind APRIL was significantly greater than either CVID B cells or B cells of relatives
(Mann Whitney test P =.024, P =.001). However, patients and relatives with mutations had
similar and reduced ligand-binding capacities (P=.104).
Impaired TACI upregulation after TLR9 activation
TLR9 activation normally upregulates TACI expression on normal B cells or B-cell lines.
Examining the EBV B cells of the large Family E allowed us to compare the effect of both
heterozygous and compound heterozygous S194X and C104R mutations with cells of
healthy controls. Fig 3, A, shows that the subject with CVID with compound heterozygous
mutations C104R/S194X and family members with heterozygous mutations C104R or
S194X had defective expression of TACI after incubation with the TLR9 agonist. At CpG
concentrations of either 1.5 or 3.0 μg/mL, controls had greater TACI expression than the
subject with CVID or her family members with mutations (Mann Whitney test P=.03.) By
contrast, the one sister with no TACI defect (E.V) had normally increased B-cell TACI
expression on TLR on activation, which was similar to the other control B cells examined.
Peripheral blood B lymphocytes of other subjects with mutations also showed impaired
baseline surface TACI. As an example, for 3 siblings, all with homozygous C104R
mutations (F.I, F.II, and F.III; only 2 of whom have CVID29), TLR9 activation increased the
lower baseline of TACI expression on the peripheral blood B cells of these subjects, but still
not into the range noted for control peripheral B cells (Fig 3, B).
TACI-induced expression of AID mRNA
Activating TACI on human B cells leads to isotype switch, initiated by the expression of
AID mRNA. We examined this aspect of TACI function in B cells of EBV cell lines from
patients and controls in Families C, E, and F, in which there were subjects with CVID with
homozygous and relatives with heterozygous mutations (Fig 4, A–C). After stimulation of B
cells with an agonist anti-TACI antibody, with or without the addition of cytokines IL-4 or
IL-10, AID mRNA was quantitated in comparison with similarly treated B cells from
healthy controls. By showing each patient with CVID (black bars) and their heterozygous
relatives (shaded bars) compared with B cells of 3 healthy controls (open bars), the
induction of AID mRNA was found significantly impaired for B cells of all subjects with
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either heterozygous or homozygous mutations in all 3 families. Although for unclear
reasons, the B cells of subjects with mutations in Family E displayed significantly reduced
AID mRNA induction when activated by cytokines IL-4 or IL-10 alone, this was not
observed for the B cells of subjects with mutations in Families C and F. However, for
experiments in which anti-TACI antibody was used to activate, the differences between
controls and subjects with mutations were even greater, with P values ranging from .02 and .
04, as marked on each figure. Data for each family were also found significantly different
with the use of one-way ANOVA, P = .002. (Note that in Family 4b, B cells of the normal
sister [also shown as an open bar] had results similar to the healthy controls.) Thus, directly
triggering TACI in each case shows a dominant class switch defect, not apparent from the
clinical phenotype (Fig 4).
APRIL-induced immunoglobulin production
To compare IgG and IgA production for subjects with CVID, their family members with
mutations, and healthy controls, PBMCs were cultured with MegaAPRIL, with or without
IL-10, or with CD40L with IL-10 as a control activator, for 13 days. Supernatant fluids were
examined for IgG (Fig 5, A) or IgA (Fig 5, B). Although variability in secretion of both
isotypes was observed, CVID relatives with TACI mutations had statistically similar
amounts of IgG and IgA production compared with control B cells (Mann-Whitney test P = .
2 and .5; ANOVA P = .16), whereas, as usual, B cells of all subjects with CVID in
comparison with controls had impaired IgG (Mann-Whitney test P = .04) and especially IgA
secretion (Mann-Whitney test P=.001). These data were also significantly different by
ANOVA (IgG, P=.038; IgA, P=.001). (Note that CVID B cells activated by CD40L+IL-10
also did not have IgG or IgA secretion comparable with normal controls, P =.01 and P =.
002.)
DISCUSSION
Although CVID is a relatively more common immune defect, it differs from many of the
other genetic defects of humans in that it often has a later onset, usually between the ages of
20 and 40 years, and an unusually heterogeneous phenotype. These distinctions have
suggested that a number of genes could contribute to the loss of B-cell function.5,6 To
unravel the complexity of this syndrome, previous studies have concentrated on multiplex
families with CVID and/or selective IgA deficiency in various members30,31 and
consanguineous families with several members with CVID.32 These studies have yielded
mutations in the T-cell activation receptor inducible costimulator and a handful of
interesting autosomal recessive defects that involve the B-cell receptor signaling pathways
or the BAFF receptor, all of which are important for B-cell survival and signaling.
Concentrating on the more numerous patients with sporadic defects, genomic studies have
shown that CVID is a complex syndrome but with a unique genetic signature, suggesting the
involvement of many genes to support numerous aspects of human immunity.7
Defects of the TACI receptor, found in 8% to 10% of patients with CVID, have provided
confirmation that TACI signaling is likely to be important in B-cell function in humans;
however, because family members uncommonly have any clinically or laboratory evident
immune defects, the role of this receptor in B-cell immunity has been unclear. However, we
show that the expression of TACI protein is reduced in B cells of both subjects with CVID
with homozygous or heterozygous mutations and their apparently healthy mutation-bearing
relatives. Perhaps as a consequence of reduced TACI expression, binding of the ligand
APRIL is also impaired. We also find that TACI expression on either lymphoblastoid B cells
or peripheral blood B cells cannot be fully enhanced by activation by TLR9 activation in
amounts comparable with control B cells. Direct triggering of the TACI receptor by an
agonistic antibody in vitro shows that all the mutations examined, even in heterozygous
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form, lead to markedly impaired upregulation of AID mRNA, a requirement for isotype
switch. However, in concert with the normal in vivo serum immune globulin levels in most
of these relatives, culturing PMBCs with APRIL, with or without cytokines, leads to
secretion of normal amounts of both IgG and IgA, unlike the B cells of subjects with CVID
with mutations, which are quite impaired. These observations lead to the conclusion that
with sufficient B-cell activation, perhaps because of the presence of additional normal
lymphoid cells and cytokines in the germinal center environment, mutation-bearing B cells
from the healthy relatives are compensated for loss of full TACI function. These factors
overall presumably lead to normal immunoglobulin production. APRIL, used as an activator
in these cultures, is known to have other binding partners, including cell surface
proteoglycans33 and BCMA, which may also allow immunoglobulin secretion.
Although one sister in one family (A.II) had severe autoimmunity, the brothers E.III and
E.VI with intracytoplasmic stop codons (S194X) had reduced serum IgM levels, and another
sister (E.IV) died at age 50 of an overwhelming septic infection, the relatives of the subjects
with CVID examined here were healthy and not overtly immune deficient. However,
specific antibody production was not examined and could be suboptimal. In this regard,
pneumococcal vaccination responses might be pertinent because TACI may exert a role in
promoting T-cell–independent antibody. Impaired B-cell expression of TACI in the neonatal
state could be related to delayed anticarbohydrate antibody responses.34 We also noted that
the loss of 1 allele of TACI in the Smith-Magenis syndrome was associated with poorer
vaccine responses to pneumococci.28
Our observations suggest that, although the role of the TACI receptor in human B-cell
biology is weak and, when impaired, cannot be said to singly cause the CVID syndrome,
selected mutations, even in heterozygous form, lead to dominantly inherited B defects that
are demonstrable in vitro.
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AID Activation induced cytidine deaminase
APRIL A proliferation-inducing ligand
BAFF B-cell activating factor
BCMA B-cell maturation antigen
CpG Cytosine phosphate guanine
CRD1 First cysteine-rich domain
CVID Common variable immunodeficiency
FACS Fluorescence-activated cell sorting
FCS Fetal calf serum
PBMC Peripheral blood mononuclear cell
TACI Transmembrane activator and calcium-modulating cyclophilin ligand interactor
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Clinical implications: Subjects with CVID have mutations in TACI, but family members
with the same mutations are generally not hypogammaglobulinemic. Here, we show that
these relatives still have detectable and selective in vitro B-cell defects.
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FIG 1.
Impaired expression of surface and intracellular TACI. The mean fluorescence intensity for
surface TACI expression (MFI; x-axis) on EBV-transformed B-cell lines of subjects and
relatives with mutations was determined and compared with the same cells examined for
intracellular TACI expression (y-axis). Subjects with CVID are shown as open circles,
relatives with mutations are shown as shaded circles, and controls are shown as black
circles. These results were compared with normal control (NL) B-cell lines with no
mutations (black circles). The subject numbers from Table I are indicated. The expression of
intracellular and extracellular TACI for all cell lines, shown for 1 experiment that was
representative of 3 performed, was highly correlated (Spearman test r = 0.8553, P = .0001).
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FIG 2.
Heterozygous mutations impair APRIL binding. B-cell lines of patients with CVID and
relatives with TACI mutations (as identified on each panel from Table I) were tested to
determine the surface binding of Mega-FLAG-APRIL, using monoclonal anti-FLAG-biotin
and phycoerythrin streptavidin, in comparison with B cells of 3 healthy controls (upper left).
These subjects are from 6 families (A–F) and also identified on each panel by the same
numbers as given in Table I. For each cell line, mean fluorescence intensity (MFI; x-axis)
for FLAG-APRIL binding is indicated in each panel for each B-cell population. Cell counts
are on the y-axis. FLAG-APRIL binding fluorescence is indicated in the open areas; controls
(biotin anti-FLAG) are marked in the shaded areas of each panel. Data shown are from 1
experiment, representative of 3 performed on these cell lines. Differences between normal B
cells (6 tested) and CVID B cells, or B cells of relatives were both significant (Mann
Whitney test P = .024, P = .001.) Patients and relatives were not different (P = .104). Note:
MFI for the 6 controls were 20, 23, 34, 26, 43, and 25.
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FIG 3.
A, TACI upregulation by TLR9 activation. EBV cells from 5 subjects from Family E were
cultured with the TLR9 agonist CpG oligodeoxynucleotide (ODN) at the indicated
concentrations for 48 hours; B-cell surface TACI expression was determined by FACS,
using biotin-labeled anti-TACI followed by streptavidinphycoerythrin. The patient with
CVID and her family members have the indicated mutations; one sister (E.V.) has no
mutation. B cells of 4 unrelated controls (NL) are included for comparison. B, Similarly,
PBMCs of subjects from 3 subjects of Family F were cultured with CpG ODN 2006 to
examine upregulation of TACI expression on peripheral blood B cells. TACI expression was
determined by FACS as for subjects in Fig 3, A. Similarly treated peripheral blood B cells of
4 unrelated controls (NL) were included for comparison. MFI, Mean fluorescence intensity.
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FIG 4.
TACI-induced expression of AID mRNA. To examine whether single or compound
mutations in TACI affect TACI activation that lead to isotype switch, the induction of AID
mRNA by an agonist anti-TACI antibody, with or without added IL-4 or IL-10, was
examined for B cells of subjects from Families C, E, and F compared with similarly treated
cells from a healthy control. The index patients with CVID (C1, E1, and F1) have 2
mutations in TACI, whereas other members are either normal or have 1 mutation. For this B
cells were cultured with biotin-labeled anti-TACI on antibiotin beads for 24 hours, and AID
mRNA was quantitated by real-time PCR. Results for AID mRNA for Family C is given in
A, Family E in B, and Family F in C. The significant differences (Mann-Whitney test) for
induction of AID mRNA for controls compared with subjects for each condition are
indicated on the figure.
Martinez-Gallo et al. Page 14
J Allergy Clin Immunol. Author manuscript; available in PMC 2013 May 07.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIG 5.
Immune globulin production in vitro. PBMCs of subjects with CVID (n = 6) or family
members (n = 6) with the same TACI mutations (C104R, A181E, S194X) or cells of healthy
controls (n 5 7) were incubated with the indicated activators for 12 days, and IgG (A) or IgA
(B) was determined. Relatives with TACI mutations had similar amounts of IgG and IgA
production in comparison with control B cells (Mann-Whitney test P = .2 and .5, and
ANOVA P = .1638), but subjects with CVID had impaired IgG (P = .04) and especially IgA
secretion (P = .001) compared with controls.
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TABLE II
Antibody evaluations
Family member Tetanus Diphtheria Measles Mumps Rubella Varicella Pneumococci Hemophilus
B.I Positive Positive Positive Positive Positive Positive 5 of 12 Positive
C.I Positive Positive — Positive Positive — 2 of 12 —
D.I Positive — — — — — 1 of 12 Negative
E.I Positive Positive Positive Positive Negative Positive 7 of 14 Negative
G.I Positive Positive — — — — — Negative
Antibodies to vaccine antigens before immune globulin replacement; the laboratory lowest level of protective was used to indicate positive; if less,
antibody was called negative. For pneumococci, after immunization with a 23-valent vaccine, tests to determine protective titers are indicated,
considering 1.3 mg/mL to be protective.
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